Biostem Technologies (BSEM) Stock Price

Biostem Technologies Price

OTC·CLOSED
3.75USD-0.06 (-1.59 %)
Market closed

Over the last 25 years Biostem Technologies grew revenue by 24.3% annually, reaching 301.83 M USD. For Biostem Technologies, the net margin of 10.6% is up versus -1,466.7% a few years ago. The stock trades about 17% above its 52-week low.

Biostem Technologies stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biostem Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biostem Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biostem Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biostem Technologies Stock Price History
DateBiostem Technologies Price
7/16/20263.75 USD
7/15/20263.81 USD
7/14/20263.80 USD
7/13/20263.99 USD
7/10/20263.69 USD
7/9/20263.20 USD
7/8/20263.25 USD
7/7/20263.32 USD
7/6/20263.26 USD
7/2/20263.24 USD
7/1/20263.20 USD
6/30/20263.26 USD
6/29/20263.48 USD
6/26/20263.49 USD
6/25/20263.44 USD
6/24/20263.89 USD
6/23/20263.70 USD
6/22/20264.07 USD
6/18/20264.00 USD
6/17/20263.91 USD
6/16/20264.15 USD
6/15/20264.09 USD
6/12/20264.08 USD
6/11/20263.36 USD
6/10/20263.43 USD
6/9/20263.57 USD
6/8/20263.68 USD
6/5/20263.90 USD
6/4/20264.04 USD
6/3/20264.12 USD
6/2/20264.17 USD
6/1/20264.18 USD
5/29/20264.14 USD
5/28/20263.91 USD
5/27/20263.99 USD
5/26/20263.91 USD
5/22/20264.14 USD
5/21/20264.10 USD
5/20/20263.99 USD
5/19/20264.29 USD
5/18/20264.41 USD
5/15/20264.32 USD
5/14/20265.19 USD
5/13/20265.07 USD
5/12/20264.97 USD
5/11/20264.55 USD
5/8/20264.50 USD
5/7/20264.11 USD
5/6/20264.15 USD
5/5/20264.37 USD
5/4/20264.40 USD
5/1/20264.45 USD
4/30/20264.51 USD
4/29/20264.55 USD
4/28/20264.72 USD
4/27/20264.60 USD
4/24/20264.83 USD
4/23/20264.49 USD
4/22/20264.73 USD
4/21/20264.64 USD
4/20/20264.52 USD
4/17/20264.97 USD
4/16/20264.60 USD
4/15/20264.68 USD
4/14/20264.86 USD
4/13/20264.83 USD
4/10/20265.13 USD
4/9/20265.20 USD
4/8/20265.13 USD
4/7/20265.69 USD
4/6/20264.93 USD
4/2/20264.57 USD
4/1/20264.16 USD
3/31/20264.03 USD
3/30/20264.11 USD
3/27/20264.43 USD
3/26/20264.99 USD
3/25/20264.92 USD
3/24/20265.12 USD
3/23/20265.49 USD
3/20/20265.07 USD
3/19/20265.08 USD
3/18/20265.14 USD
3/17/20265.13 USD
3/16/20265.18 USD
3/13/20265.29 USD
3/12/20265.24 USD
3/11/20265.16 USD
3/10/20265.05 USD
3/9/20265.14 USD
3/6/20265.21 USD
3/5/20265.49 USD
3/4/20265.78 USD
3/3/20265.36 USD
3/2/20265.55 USD
2/27/20265.64 USD
2/26/20265.29 USD
2/25/20265.65 USD
2/24/20265.80 USD
2/23/20265.79 USD
2/20/20266.05 USD
2/19/20266.22 USD
2/18/20266.28 USD
2/17/20265.72 USD
2/13/20265.80 USD
2/12/20265.52 USD
2/11/20265.50 USD
2/10/20266.28 USD
2/9/20266.74 USD
2/6/20266.24 USD
2/5/20266.72 USD
2/4/20265.95 USD
2/3/20266.50 USD
2/2/20265.37 USD
1/30/20266.17 USD
1/29/20267.05 USD
1/28/20267.69 USD
1/27/20268.20 USD
1/26/20266.54 USD
1/23/20267.15 USD
1/22/20265.29 USD
1/21/20264.69 USD
1/20/20263.84 USD
1/16/20264.20 USD
1/15/20264.59 USD
1/14/20264.99 USD
1/13/20265.11 USD
1/12/20265.30 USD
1/9/20265.00 USD
1/8/20264.25 USD
1/7/20264.73 USD
1/6/20264.26 USD
1/5/20263.93 USD
1/2/20263.91 USD
12/31/20253.81 USD
12/30/20253.80 USD
12/29/20253.84 USD
12/26/20253.87 USD
12/24/20253.88 USD
12/23/20253.86 USD
12/22/20253.99 USD
12/19/20254.24 USD
12/18/20254.40 USD
12/17/20254.00 USD
12/16/20253.84 USD
12/15/20253.95 USD
12/12/20254.14 USD
12/11/20254.27 USD
12/10/20254.45 USD
12/9/20254.19 USD
12/8/20254.33 USD
12/5/20253.95 USD
12/4/20254.28 USD
12/3/20254.34 USD
12/2/20254.65 USD
12/1/20254.56 USD
11/28/20254.86 USD
11/26/20254.83 USD
11/25/20254.11 USD
11/24/20253.91 USD
11/21/20253.96 USD
11/20/20253.85 USD
11/19/20253.75 USD
11/18/20253.33 USD
11/17/20253.35 USD
11/14/20253.97 USD
11/13/20254.14 USD
11/12/20254.65 USD
11/11/20254.57 USD
11/10/20254.60 USD
11/7/20253.72 USD
11/6/20253.87 USD
11/5/20254.10 USD
11/4/20254.02 USD
11/3/20254.38 USD
10/31/20254.84 USD
10/30/20254.64 USD
10/29/20254.66 USD
10/28/20254.50 USD
10/27/20254.70 USD
10/24/20254.77 USD
10/23/20254.86 USD
10/22/20254.89 USD
10/21/20255.31 USD
10/20/20255.30 USD
10/17/20254.87 USD
10/16/20254.71 USD
10/15/20254.83 USD
10/14/20254.70 USD
10/13/20254.12 USD
10/10/20254.31 USD
10/9/20254.60 USD
10/8/20254.80 USD
10/7/20254.83 USD
10/6/20254.78 USD
10/3/20254.96 USD
10/2/20255.05 USD
10/1/20254.99 USD
9/30/20254.69 USD
9/29/20254.84 USD
9/26/20254.97 USD
9/25/20255.08 USD
9/24/20255.09 USD
9/23/20255.06 USD
9/22/20255.04 USD
9/19/20255.16 USD
9/18/20254.96 USD
9/17/20255.22 USD
9/16/20255.30 USD
9/15/20255.25 USD
9/12/20254.98 USD
9/11/20255.51 USD
9/10/20255.83 USD
9/9/20255.86 USD
9/8/20256.18 USD
9/5/20256.70 USD
9/4/20256.72 USD
9/3/20257.15 USD
9/2/20256.56 USD
8/29/20257.10 USD
8/28/20257.30 USD
8/27/20256.38 USD
8/26/20255.97 USD
8/25/20255.75 USD
8/22/20255.80 USD
8/21/20255.96 USD
8/20/20256.15 USD
8/19/20256.48 USD
8/18/20256.55 USD
8/15/20257.04 USD
8/14/202510.38 USD
8/13/202510.68 USD
8/12/202510.30 USD
8/11/202510.05 USD
8/8/202510.35 USD
8/7/202510.37 USD
8/6/202510.66 USD
8/5/202510.86 USD
8/4/202511.49 USD
8/1/202511.26 USD
7/31/202511.96 USD
7/30/202511.52 USD
7/29/202511.36 USD
7/28/202511.10 USD
7/25/202511.64 USD
7/24/202511.86 USD
7/23/202511.06 USD
7/22/202510.87 USD
7/21/202510.75 USD
7/18/202511.25 USD
Access this data via the Eulerpool API
Get Free API Key

Biostem Technologies Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2016
620,000.00 USD
-3.13 M USD
-3.20 M USD
Jan 1, 2017
330,000.00 USD
-4.83 M USD
-4.84 M USD
Jan 1, 2020
2.52 M USD
-1.84 M USD
-2.39 M USD
Jan 1, 2021
4.34 M USD
-1.43 M USD
-1.37 M USD
Jan 1, 2023
16.69 M USD
-7.78 M USD
-8.48 M USD
Jan 1, 2024
301.83 M USD
31.20 M USD
31.88 M USD
Jan 1, 2025 (e)
232.87 M USD
40.28 M USD
5.75 M USD
Jan 1, 2026 (e)
276.73 M USD
71.58 M USD
6.42 M USD

Biostem Technologies Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 17, 2026, 10:53 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
1998199920102011201220152016201720202021202320242025e2026e
–1.001.001.00––––2.004.0016.00301.00232.00276.00
–––––––––100.00300.001,781.25-22.9218.97
–28,800.00100.00100.00––––50.0050.0093.7595.6895.6895.68
288.00288.001.001.00288.00288.00288.00288.001.002.0015.00288.00221.98264.08
–-7.00–––-2.00-3.00-4.00-1.00-1.00-7.0031.0040.0071.00
–-700.00––––––-50.00-25.00-43.7510.3017.2425.72
-1.00-8.00––-3.00-2.00-3.00-4.00-2.00-1.00-8.0031.005.006.00
–700.00–––-33.3350.0033.33-50.00-50.00700.00-487.50-83.8720.00
21.700.040.020.020.031.163.334.219.189.3213.7521.7021.7021.70
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biostem Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biostem Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biostem Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biostem Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biostem Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biostem Technologies stock margins

The Biostem Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biostem Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biostem Technologies.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2016
35.48 %
-504.84 %
-516.13 %
Jan 1, 2017
54.55 %
-1,463.64 %
-1,466.67 %
Jan 1, 2020
49.60 %
-73.02 %
-94.84 %
Jan 1, 2021
64.98 %
-32.95 %
-31.57 %
Jan 1, 2023
92.45 %
-46.62 %
-50.84 %
Jan 1, 2024
95.45 %
10.34 %
10.56 %
Jan 1, 2025 (e)
95.45 %
17.30 %
2.47 %
Jan 1, 2026 (e)
95.45 %
25.86 %
2.32 %

Biostem Technologies Stock Revenue, EBIT, Earnings per Share

The Biostem Technologies earnings per share therefore indicates how much revenue Biostem Technologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2016
0.19 USD
-0.94 USD
-0.96 USD
Jan 1, 2017
0.08 USD
-1.15 USD
-1.15 USD
Jan 1, 2020
0.27 USD
-0.20 USD
-0.26 USD
Jan 1, 2021
0.47 USD
-0.15 USD
-0.15 USD
Jan 1, 2023
1.21 USD
-0.57 USD
-0.62 USD
Jan 1, 2024
13.91 USD
1.44 USD
1.47 USD
Jan 1, 2025 (e)
10.73 USD
1.86 USD
0.27 USD
Jan 1, 2026 (e)
12.75 USD
3.30 USD
0.30 USD

Biostem Technologies business model & stock analysis

Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine.

Biostem Technologies SWOT Analysis

Strengths

Biostem Technologies Inc has a strong portfolio of intellectual property rights, including patents and trademarks, which provide a competitive advantage in the stem cell technology sector.

The company has a highly skilled and experienced management team with a deep understanding of the biotech industry.

Biostem Technologies Inc has established strategic partnerships with leading research institutions and healthcare organizations, enabling access to cutting-edge technology and expertise.

The company has a strong financial position, with a stable cash flow and a solid balance sheet.

Weaknesses

Biostem Technologies Inc faces regulatory challenges and potential legal constraints due to the evolving nature of stem cell research and therapy.

The company is heavily dependent on successful clinical trials and regulatory approvals, which can be a lengthy and costly process.

Biostem Technologies Inc operates in a highly competitive market with other established players, which creates pricing pressure and market saturation risks.

Opportunities

The increasing demand for personalized medicine and regenerative therapies presents a significant growth opportunity for Biostem Technologies Inc.

Advancements in technology and research open doors for the development of innovative treatment options, allowing the company to expand its product portfolio.

Expanding into new geographic markets with less stringent regulations can provide Biostem Technologies Inc with an opportunity to gain a competitive edge.

Threats

The potential for negative public perception and ethical controversies surrounding stem cell research poses reputational risks for Biostem Technologies Inc.

Changes in government regulations or policies related to stem cell research and therapy can significantly impact the company's operations and profitability.

Intense competition in the biotechnology industry and the emergence of new technologies could pose challenges to Biostem Technologies Inc's market position.

Biostem Technologies Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biostem Technologies historical P/E ratio, EBIT multiple, and P/S ratio

Biostem Technologies annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biostem Technologies shares outstanding

The number of shares of Biostem Technologies was 21.7 M in 2025. This indicates how many shares Biostem Technologies is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2016
3.33 M Stocks
Jan 1, 2017
4.21 M Stocks
Jan 1, 2020
9.18 M Stocks
Jan 1, 2021
9.32 M Stocks
Jan 1, 2023
13.75 M Stocks
Jan 1, 2024
21.70 M Stocks
Jan 1, 2025 (e)
21.70 M Stocks
Jan 1, 2026 (e)
21.70 M Stocks

Biostem Technologies stock splits

In Biostem Technologies's history, there have been no stock splits.
Price targets and forecasts for Biostem Technologies are not yet available.

Biostem Technologies Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/18/20260.04USD65.48 MUSD2026 Q1
5/14/20260.04USD65.48 MUSD2026 Q1
5/11/20260.04USD65.48 MUSD2026 Q1
3/24/20260.02USD56.30 MUSD2025 Q4
11/13/20250.00USD52.33 MUSD2025 Q3
8/14/20250.33USD79.76 MUSD2025 Q2
11/12/20240.37USD79.78 MUSD2024 Q3
11/11/20240.37USD79.78 MUSD2024 Q3

Biostem Technologies Executives and Management Board

MF

Mr. Michael Fortunato

(57)

Chief Accounting Officer

Compensation455,000.00 USD
JM

Mr. Jason Matuszewski

(38)

Chief Executive Officer, Director · since 2018

Compensation275,000.00 USD
AV

Mr. Andrew Van Vurst

(33)

Chief Operating Officer, Director · since 2016

Compensation275,000.00 USD
TD

Mr. Thomas Dugan

(66)

Independent Non-Executive Chairman of the Board

Compensation60,000.00 USD
BP

Mr. Brandon Poe

(55)

Chief Financial Officer, Director · since 2022

Compensation60,000.00 USD

Frequently asked questions about Biostem Technologies

The business model of Biostem Technologies Inc. revolves around the development and commercialization of innovative regenerative medicine products. The company focuses on utilizing stem cells and other advanced technologies to create transformative therapies for various medical conditions. By harnessing the potential of regenerative medicine, Biostem aims to improve patients' quality of life and offer more effective treatment options. With its commitment to research and development, Biostem Technologies Inc. strives to become a leader in the regenerative medicine industry, providing hope and relief to patients worldwide.

All fundamentals and in-depth analysis of Biostem Technologies

Our stock analysis for Biostem Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biostem Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biostem Technologies Stock
Biostem Technologies Revenue→
Biostem Technologies Stock
Biostem Technologies Net Income→
Biostem Technologies Stock
Biostem Technologies P/E→
Biostem Technologies Stock
Biostem Technologies P/S→
Biostem Technologies Stock
Biostem Technologies EBIT→
Biostem Technologies Stock
Biostem Technologies Dividend→
Biostem Technologies Stock
Biostem Technologies Directors Dealings→
Biostem Technologies Stock
Biostem Technologies Stocks→
Biostem Technologies Stock
Biostem Technologies Market capitalization→
Biostem Technologies Stock
Biostem Technologies Debt→
Biostem Technologies Stock
Biostem Technologies Liabilities→
Biostem Technologies Stock
Biostem Technologies Equity→
Biostem Technologies Stock
Biostem Technologies AAQS→
Biostem Technologies Stock
Biostem Technologies Employees→
Biostem Technologies Stock
Biostem Technologies ROE→
Biostem Technologies Stock
Biostem Technologies ROA→
Biostem Technologies Stock
Biostem Technologies ROCE→
Biostem Technologies Stock
Biostem Technologies News→
Biostem Technologies Stock
Biostem Technologies Analyst Price Targets→

Health Stocks

BioSyentBiostaxBiosynexBiostar PharmaceuticalsBioteBiosino Bio-Technology and ScienceBiotechnology AssetsBiosergenBiotequeBiosenicBiotonBioscience Animal Health PCLAll Stocks A–Z →